Capital Research Global Investors Portfolio holdings
Capital Research Global Investors (CRGI), a division of Capital Group established in 1931 and headquartered in Los Angeles, California, is a powerhouse in active investment management, overseeing hundreds of billions in assets with a focus on global equity portfolios. Known for its long-term, research-intensive approach, CRGI employs a unique multiple-portfolio-manager system to diversify risk and enhance returns, serving institutional clients, financial advisors, and individual investors through vehicles like the American Funds mutual fund family. The firm’s investment philosophy emphasizes fundamental analysis and a deep understanding of companies worldwide, aiming to identify growth opportunities over extended horizons. As part of Capital Group’s broader mission, CRGI has built a reputation for delivering consistent, value-driven results in the global investment landscape.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Meta Platforms (Facebook)
META
|
+$1.45B |
| 2 |
NextEra Energy
NEE
|
+$1.44B |
| 3 |
RTX Corp
RTX
|
+$1.37B |
| 4 |
Air Products & Chemicals
APD
|
+$1.19B |
| 5 |
Microsoft
MSFT
|
+$1.12B |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Starbucks
SBUX
|
+$2.41B |
| 2 |
Netflix
NFLX
|
+$1.67B |
| 3 |
Comcast
CMCSA
|
+$1.51B |
| 4 |
Baker Hughes
BKR
|
+$1.21B |
| 5 |
Cenovus Energy
CVE
|
+$1.14B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 26.31% |
| 2 | Healthcare | 16.23% |
| 3 | Industrials | 12.73% |
| 4 | Consumer Discretionary | 12.09% |
| 5 | Financials | 8.02% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
FISV
301
Fiserv Inc
FISV
$28B
| $71.3M | 0.02% |
536,700
| – | – |
|
302
IDEAYA Biosciences
IDYA
$3.57B
| $70.3M | 0.02% |
1,976,870
+600,000
| +44% | +$17.9M |
|
303
Emerson Electric
EMR
$89.7B
| $66.7M | 0.02% |
684,791
-508
| -0.1% | -$46.5K |
|
304
GSK
GSK
$101B
| $65M | 0.02% |
1,753,035
| – | – |
|
305
Matsons
MATX
$6.43B
| $63.5M | 0.02% |
579,528
| – | – |
|
306
Nutrien
NTR
$32.1B
| $63.1M | 0.02% |
1,119,683
| – | – |
|
307
Denali Therapeutics
DNLI
$4.03B
| $62.4M | 0.02% |
2,909,528
+29,205
| +1% | +$578K |
|
308
Guardant Health
GH
$21.7B
| $62.3M | 0.02% |
2,301,472
| – | – |
|
|
WRK
309
DELISTED
WestRock Company
WRK
| $60.1M | 0.01% |
1,447,126
+1,372
| +0.1% | +$52.8K |
|
|
CHX
310
DELISTED
ChampionX
CHX
| $59.2M | 0.01% |
2,025,494
| – | – |
|
311
Trex
TREX
$5.15B
| $58.4M | 0.01% |
705,297
+66,720
| +10% | +$4.43M |
|
|
312
Starbucks
SBUX
$126B
| $57.3M | 0.01% |
596,850
-24,769,143
| -98% | -$2.41B |
|
313
McGrath RentCorp
MGRC
$2.95B
| $55.9M | 0.01% |
+467,729
| New | +$48.6M |
|
314
Euronet Worldwide
EEFT
$2.68B
| $54.2M | 0.01% |
534,424
-764,360
| -59% | -$65.2M |
|
315
Alcoa
AA
$13.3B
| $54.2M | 0.01% |
1,592,742
| – | – |
|
316
Eastman Chemical
EMN
$8.38B
| $54M | 0.01% |
+601,726
| New | +$48M |
|
317
Enbridge
ENB
$112B
| $53.7M | 0.01% |
1,492,161
-1,567,621
| -51% | -$52.9M |
|
318
Comfort Systems
FIX
$61B
| $52.7M | 0.01% |
256,244
-42,337
| -14% | -$7.82M |
|
319
Encompass Health
EHC
$12.3B
| $52.6M | 0.01% |
787,849
| – | – |
|
|
GRFS
320
Grifois
GRFS
$5.42B
| $50.1M | 0.01% |
4,331,222
| – | – |
|
321
Glacier Bancorp
GBCI
$6.46B
| $49.6M | 0.01% |
1,200,908
+666,478
| +125% | +$22.7M |
|
322
Applied Digital
APLD
$8.93B
| $49.5M | 0.01% |
7,337,288
+5,945,559
| +427% | +$32M |
|
|
ESGR
323
DELISTED
Enstar Group
ESGR
| $48.9M | 0.01% |
165,978
| – | – |
|
324
CBIZ
CBZ
$2.96B
| $47.8M | 0.01% |
+764,193
| New | +$43.1M |
|
325
State Street
STT
$52.1B
| $46.7M | 0.01% |
602,643
-40
| -0% | -$2.79K |
|
Similar funds
Capital Research Global Investors's Q4 2023 Portfolio in Review
As of Q4 2023, Capital Research Global Investors held 429 positions worth $406B, up 12% from $363B the previous quarter. Its ten largest holdings account for 30% of the portfolio.
Capital Research Global Investors's Q4 2023 filing shows 19 new, 170 increased, 154 reduced and 21 closed positions. Its largest new stake was Sysco: 3,107,352 shares worth $227M. The largest sale was Starbucks, an estimated $2.41B.
By sector, the portfolio is most concentrated in Technology at 26% of assets, up from 24% a quarter earlier, followed by Healthcare and Industrials.
- Capital Research Global Investors's largest Q4 2023 buy was Sysco: 3,107,352 shares worth $227M.
- Capital Research Global Investors added most to Meta Platforms (Facebook) in Q4 2023, an estimated $1.45B increase.
- Capital Research Global Investors's biggest Q4 2023 reduction was Starbucks, cutting an estimated $2.41B.
- Capital Research Global Investors fully exited Cummins in Q4 2023, selling an estimated $504M.
- Capital Research Global Investors's ten largest holdings make up 30% of its $406B portfolio in Q4 2023.
- Capital Research Global Investors opened 19 new positions and closed 21 in Q4 2023.
- Capital Research Global Investors's portfolio value rose 12% quarter-over-quarter to $406B.
Based on Capital Research Global Investors's 13F filing for Q4 2023, filed 13 Feb 2024.